TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04089280

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sanprobi Barrier-multispecies probiotic
Description: Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
Study: NCT04056507

Intervention type: PROCEDURE
Intervention: Immunolabeling
Description: Immunolabeling of abnormalities observed by the cell study in flow cytometry.

Intervention type: PROCEDURE
Intervention: Immunolabeling
Description: Immunolabeling of abnormalities observed by the cell study in flow cytometry.
Study: NCT01575119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
Study: NCT03630588

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Surimi intervention
Description: The bioactive compounds used to obtain the surimi product are:~* Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~* EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~* Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi.
Study: NCT03032588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cIPV
Description: Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
Study: NCT01785186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 300 mg
Study: NCT00706459

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
Study: NCT01785186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin 10 to 35 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: isoniazid 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 400 mg
Study: NCT03261778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acromion 2.0 Brace
Description: Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acromion 2.0 Brace
Description: Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
Study: NCT01785186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrazinamide
Description: pyrazinamide 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethambutol
Description: ethambutol 275 mg
Study: NCT01812837

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Blue light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
Study: NCT01785186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethambutol
Description: ethambutol 275 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine
Description: pyridoxine 25 mg
Study: NCT02569125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 4.5 mg/m² daily
Study: NCT02494869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training
Study: NCT01785186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine
Description: pyridoxine 25 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine
Description: pyridoxine 25 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pyridoxine
Description: pyridoxine 25 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine
Description: pyridoxine 25 mg
Study: NCT01537549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid and L-acetyl carnitine
Description: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
Study: NCT03295539

Intervention type: DEVICE
Group type: OTHER
Intervention: 'Indigo' Mechanical thrombectomy system
Description: Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO
Study: NCT02108613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Sessions
Description: 8 weeks of weekly exercise classes taught by a certified exercise physiologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Volunteer
Description: Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
Study: NCT04317963

Intervention type: BIOLOGICAL
Intervention: Bezlotoxumab
Description: Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment

Intervention type: DRUG
Intervention: Standard CDI treatment
Description: Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
Study: NCT02494869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Height, Weight, BMI measure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Height, Weight, BMI measure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Height, Weight, BMI measure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study: NCT02567435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV and PO
Study: NCT01462500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
Study: NCT01483222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QUIKDRAW Pro, Aspen Medical Products
Description: Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUELLER 4581, Mueller Sports Medicine
Description: Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
Study: NCT03101293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 film-coated tablet.
Study: NCT03317145

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrostimulation (NMES) device
Description: A mobile peroneal nerve stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrostimulation (NMES) device
Description: A mobile peroneal nerve stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) device
Description: A foot pump or foot compression device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) device
Description: A foot pump or foot compression device
Study: NCT03281434

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen peptide
Description: Low leucine content protein supplement to be consumed twice daily
Study: NCT02567435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT03281434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
Study: NCT02425865

Intervention type: DRUG
Group type: OTHER
Intervention: GOLIMUMAB
Description: Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
Study: NCT01208922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV-MMX®
Description: 2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: 1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
Study: NCT03150030

Intervention type: OTHER
Intervention: Combined hyper- and hypoglycaemic clamp
Description: During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.

Intervention type: OTHER
Intervention: Combined hyper- and hypoglycaemic clamp
Description: During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.

Intervention type: DEVICE
Intervention: Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)
Description: Implantation of a loop-recorder

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)
Description: Monitoring with a continuous glucose monitor
Study: NCT03271463

Intervention type: BEHAVIORAL
Intervention: Selective Control Assessment of Lower Extremity (SCALE)
Description: Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
Study: NCT01270841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 1x daily for 3 months
Study: NCT02567435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01270841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical testosterone
Description: testosterone gel applied 1x daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Study: NCT01462695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT00875368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: maraviroc dose dependent on co-medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study: NCT04098549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid lowering of plasma glucose
Description: Rapid lowering of plasma glucose using hypoglycemic clamp technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid lowering of plasma glucose
Description: Rapid lowering of plasma glucose using hypoglycemic clamp technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow lowering of plasma glucose
Description: Slow lowering of plasma glucose using hypoglycemic clamp technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow lowering of plasma glucose
Description: Slow lowering of plasma glucose using hypoglycemic clamp technique
Study: NCT02067715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tooth bleaching
Description: The bleaching agent will be used in a single-application of 45 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tooth bleaching
Description: The bleaching agent will be used in a single-application of 45 minutes.
Study: NCT02535052

Intervention type: BIOLOGICAL
Intervention: Seasonal influenza and pneumococcal polysaccharide vaccines
Description: Vaccination

Intervention type: BIOLOGICAL
Intervention: Seasonal influenza and pneumococcal polysaccharide vaccines
Description: Vaccination
Study: NCT01400854

Intervention type: DRUG
Intervention: Effentora®
Description: prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
Study: NCT05737888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI Neurofeedback
Description: 15 intervention sessions on a 3T MRI scanner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG Neurofeedback
Description: 15 intervention sessions with a standard EEG-cap with 64 active electrodes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
Study: NCT02400905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioMimics 3D Vascular Stent System
Description: Femoropopliteal stenting
Study: NCT02194166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV or SC will be administered as described.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV or SC will be administered as described.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV or SC will be administered as described.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered in accordance with local hospital practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered in accordance with local hospital practice.
Study: NCT02867020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will receive prednisone 10mg/day.
Study: NCT03707483

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination of vitamin C and platelet rich fibrin
Description: combination of vitamin C and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination of vitamin C and platelet rich fibrin
Description: combination of vitamin C and platelet rich fibrin
Study: NCT00897442

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies